MedTrace Logo

Single Ascending Dose Study (SAD) iv Formulation

NCT00688831 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2010-12-02

No results posted yet for this study

Summary

The purpose is to study the safety of AZD1305, how AZD1305 is tolerated and how the medication is metabolised by the body (how it is taken up into the body, distributed around the body and disappears from the body

Conditions

  • Healthy

Interventions

DRUG

AZD1305

Solution for iv infusion , single dose

DRUG

Placebo

NaCl solution for iv infusion, single dose

Sponsors & Collaborators

Principal Investigators

  • Helen Lunde, MD · AstraZeneca R&D, Mölndal, Sweden

  • Marianne Hartford, MD, PhD · AstraZeneca, Clinical Pharmacology Unit, Sahlgrenska University Hospital, Göeborg, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2008-05-31
Completion
2008-05-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00688831 on ClinicalTrials.gov